Edwards Lifesciences Corporation

NYSE:EW Voorraadrapport

Marktkapitalisatie: US$41.0b

Edwards Lifesciences Beheer

Beheer criteriumcontroles 3/4

De CEO Edwards Lifesciences is Bernard Zovighian, benoemd in May2023, heeft een ambtstermijn van 1.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.87M, bestaande uit 7.6% salaris en 92.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.012% van de aandelen van het bedrijf, ter waarde $ 5.02M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.2 jaar en 4.5 jaar.

Belangrijke informatie

Bernard Zovighian

Algemeen directeur

US$12.9m

Totale compensatie

Percentage CEO-salaris7.6%
Dienstverband CEO1.5yrs
Eigendom CEO0.01%
Management gemiddelde ambtstermijn5.2yrs
Gemiddelde ambtstermijn bestuur4.5yrs

Recente managementupdates

Recent updates

Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Nov 11
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts

Oct 25

Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates

Sep 11
Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Aug 30
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Aug 17
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut

Jul 26

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Jul 26
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Jul 12
Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Jun 24
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Edwards Lifesciences Corp Looks Bullish (Technical Analysis)

Jun 22

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

May 13
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)

May 09

When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Apr 29
When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Apr 15
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Apr 01
Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Feb 21
Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)

Feb 14

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Feb 08
Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

Jan 28
Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Jan 14
The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Jan 09

Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Dec 31
Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Dec 17
Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets

Oct 26

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Oct 23
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Oct 09
Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Sep 26
Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Sep 11
A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences: Rising Dominance In Structural Heart Disease

Aug 21

Analyse CEO-vergoeding

Hoe is Bernard Zovighian's beloning veranderd ten opzichte van Edwards Lifesciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

US$2b

Jun 30 2024n/an/a

US$2b

Mar 31 2024n/an/a

US$1b

Dec 31 2023US$13mUS$973k

US$1b

Sep 30 2023n/an/a

US$1b

Jun 30 2023n/an/a

US$1b

Mar 31 2023n/an/a

US$1b

Dec 31 2022US$3mUS$642k

US$2b

Compensatie versus markt: De totale vergoeding ($USD 12.87M ) Bernard } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).

Compensatie versus inkomsten: De vergoeding van Bernard is het afgelopen jaar met meer dan 20% gestegen.


CEO

Bernard Zovighian (56 yo)

1.5yrs

Tenure

US$12,869,020

Compensatie

Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Bernard Zovighian
CEO & Director1.5yrsUS$12.87m0.012%
$ 5.0m
Scott Ullem
Corporate VP & CFO10.8yrsUS$5.95m0.046%
$ 19.0m
Donald Bobo
Corporate Vice President of Strategy & Corporate Development8.8yrsUS$4.29m0.035%
$ 14.3m
Larry Wood
Corporate VP and Group President of TAVR & Surgical Structural Heart1.8yrsUS$5.40m0.030%
$ 12.4m
Andrew Dahl
Principal Accounting Officerless than a yeargeen gegevens0.00030%
$ 123.0k
Todd Brinton
Corporate VP of Advanced Technology & Chief Scientific Officer5.8yrsgeen gegevensgeen gegevens
Mark Wilterding
Vice President of Investor Relationsno datageen gegevensgeen gegevens
Arnold Pinkston
Corporate VP & General Counsel5.2yrsgeen gegevensgeen gegevens
Dirksen Lehman
Corporate Vice President of Public Affairs11.4yrsgeen gegevensgeen gegevens
Christine McCauley
Corporate Vice President of Human Resources12.3yrsgeen gegevensgeen gegevens
Gary Sorsher
Senior Vice President of Quality & Regulatory Compliance1.3yrsgeen gegevensgeen gegevens
Wayne Markowitz
GM & Senior VP of Surgical Structural Heart1.3yrsgeen gegevens0.00021%
$ 86.1k

5.2yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EW is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.2 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Bernard Zovighian
CEO & Director1.5yrsUS$12.87m0.012%
$ 5.0m
Kieran Gallahue
Independent Director9.8yrsUS$335.06k0.012%
$ 5.0m
Paul LaViolette
Independent Director4.3yrsUS$329.97k0.0013%
$ 537.3k
Steven Loranger
Independent Director8.7yrsUS$335.06k0.012%
$ 5.0m
Leslie Heisz
Independent Director8.3yrsUS$356.42k0.0046%
$ 1.9m
Nicholas Valeriani
Independent Chairman10yrsUS$347.97k0.012%
$ 4.8m
Leslie Davis
Independent Directorless than a yeargeen gegevensgeen gegevens
David Feinberg
Directorless than a yeargeen gegevensgeen gegevens
Ramona Sequeira
Independent Director4.5yrsUS$334.97k0.0019%
$ 767.0k

4.5yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EW wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).